Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, PGD2 was shown to increase testosterone production in human keratinocytes through reactive oxygen species, suggesting potential benefits of antioxidants like N-acetyl-cysteine for AGA patients.

This letter to the editor about prostaglandins in androgenetic alopecia in men and women reports no new research findings.

This study found that increased levels of PGD2 and prostacyclin and decreased levels of PGE2 and PGF2α were associated with baldness in androgenetic alopecia, suggesting potential targets for treatment.

This meta-analysis found that topical prostaglandin analogs could significantly improve hair length and density in patients with hair loss, compared to placebo, without notable safety differences.

This study demonstrated that PGF 2α significantly stimulates hair growth in human hair follicles via a receptor-driven mechanism, with a notably stronger response in intermediate follicles than in terminal ones, suggesting potential clinical significance for conditions like alopecia.

This study found no significant difference in urinary androgen and prostaglandin levels between male pattern baldness patients treated with finasteride for one year and normal controls.

A substance called prostaglandin D2 is found more in bald scalps and it stops hair from growing. Blocking its receptor could potentially treat hair loss.

Prostaglandin D2, found in higher levels in bald scalps, stops hair growth and could be a target for treating hair loss.

Prostaglandin D2, found in higher levels in bald scalps, stops hair growth, suggesting that blocking its receptor could potentially treat hair loss.

This case report discusses the use of a prostaglandin analogue for treating eyebrow loss in a patient with frontal fibrosing alopecia, but provides no new clinical results.

This study suggests that the expression of the DP2 receptor is higher in balding scalp cells and that its knockdown could inhibit the transition to the catagen phase in cultured human hair follicles, potentially counteracting hair growth inhibition associated with male pattern baldness.

This article presents a case report of a child with coexisting alopecia areata and vitiligo showing improvement with topical prostaglandin E2 treatment, without reporting new clinical results.

In this study, PGD2 treatment in keratinocytes increased testosterone production via reactive oxygen species, suggesting a potential role for the NRF2 pathway in androgenic alopecia treatment strategies.

This study found that prostaglandin D2 increases testosterone production in human keratinocytes through a mechanism involving ROS and REDOX potential, which could inform treatments for androgenic alopecia.

This review discusses the potential applications of prostaglandin F2α analogs for certain types of alopecia and hypopigmentation, but reports no new experimental results.

This study found that prostaglandin D2 reduced proliferation in bulge resident K15+ stem cells but not in other K15+ progenitor cells, suggesting differential impacts on hair follicle stem cell niches.

In this pilot study, topical latanoprost acid was observed to increase hair count and improve hair follicle structure in women with androgenetic alopecia, with no serious adverse events, suggesting potential for further investigation to confirm its efficacy and safety.

This review concluded that while topical prostaglandin analogues show some potential in treating androgenetic alopecia, evidence is still limited and no products have regulatory approval.

In this study, 15d-PGJ2 administered in a topical cream inhibited oxidative and inflammatory skin changes caused by UVB radiation in hairless mice, suggesting it as a promising treatment approach.

This review discusses the roles of prostaglandins in hair loss and highlights their potential as targets for new alopecia treatments, but reports no new clinical findings.

This review discusses genetic contributions to androgenetic alopecia and proposes focusing on candidate genes in genome-wide association studies, but it reports no new clinical results.

This study found that prostaglandin metabolism enzymes are present in human hair follicles, suggesting a potential role in hair growth and differentiation, with some expression differences between men and women.

This article discusses various periocular conditions like madarosis, milphosis, trichomegaly, and dermatochalasis, and highlights their potential link to underlying local and systemic diseases, but reports no new clinical findings.

This study found that transgenic expression of COX-2 in mouse basal keratinocytes causes epidermal hyperplasia and certain dysplastic features at specific body sites.

This study suggests that the COX-2 enzyme plays a role in hair follicle biology, as transgenic overexpression in mice induced hair follicle cycling disturbances and alopecia, which was mitigated by COX-2 inhibition.

This study found that overexpression of sPLA2-X in mice was associated with alopecia and hair follicle abnormalities, highlighting its potential role in hair follicle homeostasis.

This study found that Grateloupia elliptica extract may help treat hair loss by promoting dermal papilla cell proliferation, inhibiting 5α-reductase, and reducing inflammation in various cell types.

This study found that prostaglandin D2 promotes androgen receptor and AKT signaling in human dermal papilla cells through the DP2 receptor, potentially contributing to androgenetic alopecia.

This study found that HMGB1 enhanced hair growth by stimulating PGE2 production in human dermal papilla cells, suggesting a potential therapeutic target for alopecia treatment.